IP Library Granted Patent US 8,282,939
Granted Patent B2
US 8,282,939 · App. 12/879,335 · Granted Oct 9, 2012

Attenuated live triple G protein recombinant rabies virus vaccine for pre- and post-exposure prophylaxis of rabies

Assignee: Thomas Jefferson University
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,282,939
App. No.
12/879,335
Granted
Oct 9, 2012
Kind
B2
Abstract

The invention provides a recombinant rabies viruses comprising three copies of a mutated G gene wherein each G gene encodes a rabies virus glycoprotein having the amino acid 194 mutated to a serine and the amino acid 333 is mutated to a glutamic acid. The recombinant rabies virus is nonpathogenic in immunodeficient mammals and can be used in a vaccine to induce an immune response protect mammals from infection by rabies virus as well as clear a pre-existing rabies virus infection from neural tissues.

Claims (9)

1. A nonpathogenic recombinant rabies virus comprising at least three copies of a mutated G gene, wherein said mutated G gene encodes a rabies virus glycoprotein wherein the amino acid 194 is serine and the amino acid 333 is glutamic acid in the glycoprotein.

2. The recombinant rabies virus of claim 1 , wherein said mutated G gene is encoded by SEQ ID NO:7.

3. The recombinant rabies virus of claim 1 further comprising a foreign antigen.

4. The recombinant rabies virus of claim 3 wherein said antigen is derived from a human or an animal pathogen.

5. The recombinant rabies virus of claim 1 further expressing a gene encoding an immune-stimulatory protein.

6. A vaccine comprising the recombinant rabies virus of claim 1 .

7. A pharmaceutical composition comprising the recombinant rabies virus of claim 1 , and a pharmaceutically acceptable carrier.

8. A method of inducing an immune response to rabies virus in a mammal, comprising administering to said mammal an effective amount of a nonpathogenic recombinant rabies virus comprising at least three copies of a mutated G gene, wherein said mutated G gene encodes a rabies virus glycoprotein wherein the amino acid 194 is serine and the amino acid 333 is glutamic acid in the glycoprotein.

9. A method of protecting a mammal from rabies virus, comprising administering to said mammal an effective amount of a nonpathogenic recombinant rabies virus comprising at least three copies of a mutated G gene, wherein said mutated G gene encodes a rabies virus glycoprotein wherein the amino acid 194 is serine and the amino acid 333 is glutamic acid in the glycoprotein.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 28, 2010
From: FABER, MILOSZ; DIETZSCHOLD, BERNHARD; HOOPER, DOUGLAS CRAIG
To: THOMAS JEFFERSON UNIVERSITY
Reel/Frame 025053/0571 →
CONFIRMATORY LICENSE Recorded Sep 23, 2010
From: THOMAS JEFFERSON UNIVERSITY
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 025033/0504 →
Continuity (2)
Provisional Application 61241439 · Sep 11, 2009
Related Publication 20110064764A1 · Mar 17, 2011